Should I buy Moderna (MRNA) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $89 (-38 %), call made on August 21, 2026, maturing on August 21, 2027 (7 d ago).
Firm-by-firm track record on Moderna
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Barclays | 33 % | +14.7 % | 6 | $125 -12% |
| JP Morgan | 60 % | -1.6 % | 5 | $77 -46% |
| UBS | 50 % | -2.8 % | 6 | $150 +5% |
| Goldman Sachs | 17 % | -8.5 % | 6 | $120 -16% |
| Piper Sandler | 20 % | -28.5 % | 10 | $77 -46% |
| RBC Capital | 0 % | -55.8 % | 9 | $45 -68% |
| Chardan Capital | 62 % | +123.6 % | 8 | — |
| Oppenheimer | 40 % | +22.9 % | 5 | — |
✅ Reasons to believe
- Few solid positives from analysts right now: of 12 ratings, only 2 buys, and the median price target ($77) is -46% below the price ($143). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on MRNA, Morgan Stanley (100% hit rate, 4 scored calls), only targets $89 (call made on August 20, 2026, maturing on August 20, 2027) (-38%) in its most recent call, and $32 (call made on October 10, 2025, maturing on October 10, 2026) (-78%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 12 ratings, 8 are neutral and 2 are sells.
- Limited upside: the median target is only -46% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on MRNA
Median target $77 (-46%) · 12 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Moderna now?
We won't decide for you. The facts: 17% of analysts rate it a buy, median target $77 (-46%), and Morgan Stanley (most reliable on MRNA, 100%) targets $89. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Moderna?
The stated upside is small: the median target ($77) sits just -46% from the price ($143) (most reliable on MRNA: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Moderna still worth investing in?
It depends on the gap between the price ($143) and its estimated value: analysts target $77 on median (-46%), with 17% buys (most reliable on MRNA: Morgan Stanley, 100%). Cross-check with their real reliability on MRNA and the cautions above. Information, not advice.
What's the main risk in buying MRNA?
Even the most reliable firm on MRNA, Morgan Stanley (100% hit rate, 4 scored calls), only targets $89 (call made on August 20, 2026, maturing on August 20, 2027) (-38%) in its most recent call, and $32 (call made on October 10, 2025, maturing on October 10, 2026) (-78%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Moderna profile (consensus, analyst reliability, price target, performance).